2. 2
Lab Testing Division (LTD) at WuXi AppTec
An Engine to Support Drug Discovery Initiatives
• Strong financial growth fuels continued investment in nurturing talents and developing service
capabilities
• Synergistic businesses in the discovery, preclinical and clinical stages delivering end-to-end services for
PCC nomination and IND/NDA filings
Well-resourced Infrastructure
• 8 Major business platforms
• ~2,000 employees with seasoned leaders, proven scientific credentials and operational expertise
• Established global operations in both China and the U.S. with continued momentum
Unmatched Operational Scale
• One of Wuxi AppTec’s largest divisions with significant contribution to top line and cash flow
• Strong YTY growth driven by several cutting edge businesses
Growth Engine
3. 3
Testing Solutions for Drug Development
We provide a world class, fully integrated testing
solution enabling scientists to transform their ideas into the best
healthcare products, moving science from research bench to
hospital bed, in order to better serve our community.
We serve as a healthcare “Silk Road”, which enables
advanced technologies to enter the Chinese market effectively,
by leveraging our deep regulatory expertise, wide reaching sales
and marketing network.
We endeavor to transform ideas into the best healthcare products by offering integrated testing
solutions
4. 4
Global Operations
LTD Site
Other WuXi Site
Tianjin
ASU
Suzhou
ONC, DMPK, BAS, TOX, MD
Shanghai (Division Headquarter)
ASU, BIO, ONC, IMMU, DMPK, BAS
Wuhan
ASU
Nanjing
DMPK, BAS
Plainsboro New Jersey
BIO, DMPK, BAS
ASU: Analytical Service Unit
BIO: Biology
ONC: Oncology
IMMU: Immunology Center
DMPK: Drug Metabolism &
Pharmacokinetics
BAS: Bioanalytical Services
TOX: Toxicology
MD: Medical Device
5. 5
Synergistic Portfolio
(TOX) Toxicology
(DMPK) Drug Metabolism & Pharmacokinetics
(BIO) Biology
(ASU) Analytical Chemistry & Separation; Analytical Development & Stability
Preclinical
Discovery
Screening
Candidate
Nomination
Lead
Optimization
Clinical Market
A complete value chain supporting all phases of drug discovery
2. IND/NDA Package(ONC) Oncology
1. Discovery Package
(IMMU) Immunology Center
(MD) Medical Device Testing
(BAS) Bioanalytical Services
3. Device Package
6. 6
Analytical Service Unit
Analytical Solution from FDA, MPA and CFDA Inspected Laboratories
The ONLY China-based CRO passing all FDA, MPA and CFDA inspections
One of the world largest stability storage and testing facilities
(30,000+ ft3 chamber spaces available)
Submission-ready CMC Dossiers prepared for global or China submission
GMP and non-GMP chiral and achiral separations (mg to multi-kg)
100+ client-initiated audits from the US, EU and Japan since 2006
Successfully filed 6 INDs to the FDA and 6 CTAs to CFDA
Stability programs completed for 700 batches of API & drug products
500+ early phase & 19 NDA/MAA stability programs
Dedicated teams can perform 10,000 separations per year
7. 7
Biology
Better Treatments Begin with Better Screening Platform and Better Disease Models
Globally recognized platform for antiviral R&D services including HBV, HCV, and
respiratory viruses
State-of-the-Art in vitro screening platform with Mosaic –controlled compound
management system and Abase-enabled data management system
Leading CRO in China for PK/PD capabilities in NASH, diabetes, and CNS/Pain
1st telemetry Electroencephalography (EEG), Electro-Oculogram (EOG),
Electromyography (EMG) monkey models in China .
1st clinical virology lab with CLIA certification supporting global and domestic HBV and
HCV clinical studies
1st GLP electrophysiology (e.g. hERG testing) lab in China
In vitro assay development and transfer: High/medium Throughputs Screening ( HTS & MTS ) and structure
activity relationship (SAR) iteration
In vivo model development and transfer; efficacy testing; PK/PD analysis; in vivo ephys capabilities
Early in vitro tox profiling panel: 90+ kinases, 10+ ion channels, 20+ GPCRs
Since 2008, 20+ preclinical candidates (PCC) delivered ; 10+ in IND stage, 5 moved into phase I clinical
trials, 2 entered phase II clinical trials, 1 in phase III clinical trials with FDA breakthrough therapy designation.
8. 8
Oncology
Benefiting Cancer Patients through an Innovative Platform
End to end Solution & Service with innovative platforms.
CRISPR · Tumor model · Immuno – oncology · Transactional science.
CRISPR/Cas9 Gene Editing Platform for target ID, validation, and
understanding of drug-resistance mechanism.
An Industry Leading oncology service platform with PDX, CDX,
syngeneic animal models
AAALAC accredited animal facilities in Shanghai and Suzhou
World class Integrated tumor model online database (onco.wuxiapptec.com)
~950 PDX models, 150 CDX models, ~50 syngeneic mouse tumor models
World’s largest collection of Asia-prevalent PDX models
460+ PDX models characterized by whole exome sequence/RNAseq/ expression/SNP 6.0
arrays
9. 9
Immunology Center
Efficacy and MoA studies to facilitate immunotherapy drug discovery
Numerous autoimmune diseases and inflammation animal models
Histopathology core equipped with best-in-class automated
systems for high throughput tissue biomarker analysis
Advanced Flow Cytometry core with 18-color cellular biomarker
analysis and cell sorting capability
20+ validated tissue biomarkers in IHC, FISH or DISH platform with Ventana Discovery Ultra.
Validated cellular biomarker analysis of all major hematopoietic cell subsets in lymphoid organs,
tumor microenvironment and peripheral blood etc.
10+ well-established animal models in rheumatic arthritis, multiple sclerosis, psoriasis, colitis etc.
CAP accreditation and GCP compliance
AAALAC accredited SPF animal facility
10. 10
Drug Metabolism & Pharmacokinetics
Where Pharmacy and Physiology Intersect
Services from discovery screening to NDA filing both in China and the US
ADME assays validated against literature data to ensure accuracy and reliability
Quantitative whole-body autoradiography (QWBA) studies offered in the US
Radioanalysis for both clinical (hAME) and nonclinical trials and assays (3H and 14C)
Early discovery assays are highly automated to support high throughput screening
Large panel of complicated surgical models offered in rats, dogs and NHPs
Passed FDA ,CFDA and AAALAC inspections
Experienced laboratory staff with AALAS certificates
30+ global partners in new drug discovery leading to 12 PCCs in 2014
350+ global clients involved in ~100 novel drug IND/NDA studies since 2009 (FDA and CFDA)
200+ canine and 200+ non-human primate (NHP) colonies dedicated for PK studies
100+ NHP colonies for PD/PK studies in; diabetes, obesity, dyslipidemia, arthritis, stroke, fibrosis, Parkinson’s
11. 11
Bioanalytical Services
Help Define the Best Therapeutic Opportunities
The largest GLP regulated Bioanalytical lab in Asia with satellite operations in the US
Nonclinical and clinical support for generic, innovator, biosimilars and biomarkers
Top of the line equipment including API-6500 LCMS, GYROS, Dual MSD
Rigorous training program authorized by the CFDA
Custom in-house antibody production through Abgent to support large molecule studies
Samples managed by Watson LIMSTM
Passed FDA, EMA, OECD and CFDA inspections
1st CLIA certified Central Lab in China
2,000+ clinical trials supported collectively, 600,000+ samples analyzed per year
Over 100 active clients and preferred vendor for 6/20 top multinational pharmaceutical
companies
Fully validating (PK, ADA, Nab) top biologics to provide off-the-shelf analysis for biosimilars.
12. 12
Toxicology (Drug)
Ensuring Safe and Reliable Pharmaceutical Products
Passed FDA, OECD and CFDA GLP inspections
850+ general toxicology/safety pharmacology studies since 2011
140+ IND/NDA packages delivered since 2011
Passed 75+ sponsors’ GLP QA and animal welfare audits
“ [WuXi Toxicology] maintains an exemplary program of animal care.”
- AAALAC 2013 inspection report
One of the largest animal testing facilities in Asia at 314,000 ft2
Housing up to 1,800 NHPs at a given time in US- or EU-compliant caging
Double-barrier housing for rodents (CFDA and PMDA requirement)
All animal vendors audited by ACLAM- vet led staff and QA dept. to ensure quality
Experienced study directors (4 DABT/ERT) and robust training program for technicians.
Reports can be provided in SEND-format
13. 13
Medical Device
Ensuring Safe and Reliable Medical Device Products
An extension of WuXiAppTec’s US medical device experience
Biosafety Assessment & Biocompatibility Test (Annex A ISO-10993-1)
Safety consideration associated with extractable and leachable
Regulatory consulting
CFDA fling for international and China customers
Global filing for China customers
Tests for Cytotoxicity
Tests for Genotoxicity
Tests for Hemocompatability
Tests for Implantation
Tests for Sensitization
Tests for irritation or Intracutaneous reactivity
Tests for Pyrogenicity
Tests for Systemic toxicity (acute)
Test for subacute and subchronic toxicity
Extractable and Leachable testing
Annex A ISO-10993-1
14. 14
LTD’s Core Competitive Advantages
LTD
Resource
Capability
Qualification
Most comprehensive and integrated CRO with an unmatched portfolio
Best positioned to support domestic and global drug discovery customers
Talent Resource
Financial Strength
Global Footprint
Strong Connections with
Pharmaceutical and
Biotechnology Companies
Gateway to China Market
1st CMC platform in China
inspected by FDA
1st GLP preclinical laboratory
in China that is double certified
with an OECD country and
CFDA, passed FDA inspection
1st GLP/GCP bioanalytical lab
in China that passed FDA,
OECD, and CFDA inspections